GeneDx reports Q2 adjusted EPS 50c, consensus 11c

Reports Q2 revenue $102.7M, consensus $85.58M. Cash, cash equivalents, marketable securities and restricted cash was $135.5M as of June 30. “Crossing the $100M revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx (WGS), putting us on a path for more growth at scale and enabling us to reach more patients while reducing unnecessary spend across the global healthcare system,” said Katherine Stueland, CEO. “Our strong Q2 performance was driven by our core business, underscoring its strength and resilience. These results, coupled with the ever-expanding opportunities ahead, including general pediatrics, demonstrate that we’re just beginning to deliver on the promise of how our technology can fundamentally change the way genomics can inform healthcare, shifting from reactive to proactive care.”